GET A VALUABLE CERTIFICATE FOR JOB MARKET


ACADEMIC RECOGNITION OF 3 OR 6 CREDITS


DESIGNED FOR EXPERTS BY EXPERTS


ADVANCED QUANTITATIVE BENEFIT-RISK ASSESSMENT METHODS IN DECISION MAKING ON MEDICINES


OBJECTIVES



Decision making on medicines informed by quantitative benefit-risk assessment may differ depending on the perspective of the decision maker and the phase of drug development.

This module will address the decision-making on medicines by different stakeholders and how to apply advanced benefit-risk assessment tools in this process.

Applied decision making, individualized benefit-risk assessment, real life data, graphical representation

 

MODULE PARTS



  1. Multi-criteria decision analysis
  2. Conjoint analysis
  3. Personalized benefit-risk assessment

 

TRAINER TEAM



Coordinator: Dr Rianne Van Den Ham (from Utrecht Universiteit)

Expert(s): Prof Olaf Klungel, Dr Jet Van Der Zijden, Dr Tjeerd Van Staa, Dr Rob Heerdink, Prof Anke-Hilse Maitland-Van Der Zee, Yasmina Noorsyahdy Alif (from Utrecht Universiteit), Dr Filip Mussen, Edmond Chan (from Janssen Pharmaceutica NV).

Advanced level
75 h workload over 3 months (3 ECTS credits)
Key dates
Course calendar
Certificate award
or included in Master Year 2 or PhD programme
English language
Online based learning
Student: 1,500 €
Professional: 3,000 €
  Savings could be offered under eligibility conditions.

APPLY NOW

Applications open until March 23rd, 2018

Or include this module in your training curriculum choices...

Master Year 2 PhD



Confused? Read the FAQs...

NEED TO TALK TO US?

+33 5 47 30 42 69

Monday-Friday / 9.00am-6.00pm CET

 

Supported By

IMI logo EU logo efpia logo

Created By

Eu2P Partners